- Topic
18k Popularity
3k Popularity
2k Popularity
18k Popularity
31k Popularity
17k Popularity
7k Popularity
142k Popularity
68k Popularity
1747k Popularity
- Pin
- #Gate Ranks Top 4 Exchange#
Gate has reached the Top 4 global crypto derivatives exchanges on CoinMarketCap, with a 24-hour trading volume exceeding $15 billion. Enjoy some of the lowest fees in the industry—maker fees as low as 0.015%. Gate is committed to providing users with a more efficient and cost-effective trading experience, making it your top choice for crypto trading!
Start trading now:
👉 Spot Trading: https://www.gate.com/trade
👉 Alpha Trading: https://www.gate.com/alpha
👉 Futures Trading: https://www.gate.com/futures
💬 What derivatives or other products have you recently traded
- 🎉 CandyDrop 5.0: 5 BTC Mega Airdrop is here!
🎁 Total Prize Pool: 5 BTC
📈 Trade any futures pair ≥ 50,000 USDT to earn Candy
👥 Invite friends to unlock more BTC rewards
🗓️ Event Time: June 27, 9:00 – July 11, 9:00 (UTC)
🎯 Max reward per user: 0.01 BTC
👉 Join Now >> https://www.gate.com/candy-drop/detail/BTC-59
⚡ 100% real airdrop — limited time only!
- Gate Alpha 2nd Points Carnival Round 4 Hot Launch! Trade to Share $30,000 MORE & Alpha Points
Trade $MORE to unlock Listing Airdrops + $300K Points Prize Pool!
💰 Total Airdrop Volume: $30,000 MORE, Limited slots—first come, first served!
✅ Total Points: 2 Alpha Points per trade—accumulate points to share the $300K prize pool!
🔥Trade the Hottest On-Chain Assets First
For more information: https://www.gate.com/campaigns/1342alpha?pid=X&c=MemeBox&ch=vxDB0fQ5
- 📢 $MORE is launching on Gate Alpha!
Users will be able to trade Moonveil ( $MORE ) directly via Gate Alpha — Gate's one-stop on-chain trading portal.
🔥Trade the Hottest On-Chain Assets First
https://www.gate.com/alpha
- 🎁 Gate Alpha Airdrop Alert!
To celebrate the listing of $EGL1 on Gate Alpha @GateioAlpha
A limited-time airdrop campaign is now live — with 149,254 EGL1 up for grabs!
First Come, First Served
🔥Trade the Hottest On-Chain Assets First
For more information: https://www.gate.com/campaigns/1355?pid=X&ch=0cykUS3i
Rongchang Bio responds to Pfizer's $200 million impairment of Vidisutuximab: Pfizer's conclusion is based on market competition environment.
On February 7th, Jinshi Data reported that Rongchang Biology responded to the reporter's inquiry about the devaluation of its vedolizumab (RC48) by its partner Pfizer, which amounted to a reduction of 200 million US dollars. Rongchang Biology stated that this devaluation is due to changes in the market competitive environment compared to the time of the transaction, and some indications for vedolizumab have not progressed as expected, resulting in a decrease in expected value compared to the transaction time. This conclusion was made by Pfizer based on its judgment of the market competitive environment. Previously, in August 2021, Rongchang Biology authorized the overseas rights of its HER2ADC (antibody-drug conjugate) vedolizumab to ADCleading company Seagen. In 2023, Seagen was acquired by Pfizer. Currently, Pfizer is advancing the indication of vedolizumab for urothelial carcinoma overseas.